<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643589</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-201304-K1(02)</org_study_id>
    <nct_id>NCT02643589</nct_id>
  </id_info>
  <brief_title>Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell Transplantation</brief_title>
  <official_title>Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central South University Xiangya Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the incidences of GVHD in haploidentical
      hematopoietic stem cell transplant recipients receiving different dose of antithymocyte
      globulin (ATG) for acute graft-versus-host disease(aGVHD) prophylaxis. The investigators'
      first objective was to investigate the optimal dose of ATG for aGVHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Graft-versus-host diseases (GVHD) remains a major cause of morbility and mortality after
      allogeneic hematopoietic stem cell transplantation (HSCT) with grafts from an HLA-mismatched
      family donor. Antithymocyteglobulin (ATG) has been widely used to prevent acute GVHD (aGVHD)
      in haploidentical HSCT. Notwithstanding, immunosuppressive effect of ATG, which may also
      increase the risk of opportunistic infections, necessitates the use of the lowest possible
      dose. Till now, the optimal dose of ATG is not known. Here, the investigators compared the
      outcome of patients receiving haploidentical HSCT treated with two different doses of ATG.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute GVHD</measure>
    <time_frame>1 years</time_frame>
    <description>Acute GVHD was graded according to standard criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>3 years</time_frame>
    <description>Immune reconstitution is performed every 3 months after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Survival includes overall and disease-free survival within 2 years after transplantation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>ATG 7.5mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG 10mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.</description>
    <arm_group_label>ATG 7.5mg/kg</arm_group_label>
    <arm_group_label>ATG 10mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Haploidentical hematopoietic stem cell transplant recipient

          -  Subjects (or their legally acceptable representatives) must have signed an informed
             consent document indicating that they understand the purpose of and procedures
             required for the study and are willing to participate in the study

        Exclusion Criteria:

          -  Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood
             pressure)

          -  Patients with any conditions not suitable for the trial (investigators' decision)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifa Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ren Lin</last_name>
    <phone>+86-020-62787883</phone>
    <email>lansinglinren@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ren Lin</last_name>
      <phone>+86-020-62787883</phone>
      <email>lansinglinren@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ottinger HD, Ferencik S, Beelen DW, Lindemann M, Peceny R, Elmaagacli AH, Husing J, Grosse-Wilde H. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood. 2003 Aug 1;102(3):1131-7. Epub 2003 Apr 10.</citation>
    <PMID>12689945</PMID>
  </reference>
  <reference>
    <citation>Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Barbanti M, Sacchi N, Van Lint MT, Bosi A. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001 Nov 15;98(10):2942-7.</citation>
    <PMID>11698275</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>haploidentical hematopoietic Stem Cell Transplantation Antithymocyte globulin</keyword>
  <keyword>acute graft-versus-host disease</keyword>
  <keyword>antithymocyte globulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

